Engineered Macrophage Membrane-Coated Nanoparticles for Hepatic Ischemia–Reperfusion Injury Therapeutics
Biomaterials Research · 2025-01 · 29
DOI: 10.34133/bmr.0212 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomaterials Research, online erschienen am 23.05.2025. Verfasst von Long Yang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Chongqing, Chongqing Graduate Student Research and Innovation Programme.
Abstract (Originalsprache)
Hepatic ischemia–reperfusion injury (HIRI) is a common perioperative complication occurring after liver transplantation and can lead to further problems such as early allograft dysfunction (EAD). Currently, the treatment options for HIRI are extremely limited. In this study, we used bioinformatics analysis to elucidate the critical role of neutrophil chemokines (CXC chemokines) in HIRI. By analyzing sequencing data from the hepatic tissue of posttransplant patients with EAD and the reperfused animal model, we discovered that hepatocytes and macrophages are the primary cells secreting CXC chemokines, and the activation of the nuclear factor kappa B (NF-κB) signaling pathway is the main driver of their secretion. Melatonin (MT) can protect cells from oxidative harm while also inhibiting NF-κB signaling, suggesting its potential to ameliorate HIRI. Accordingly, we designed a nanoparticle platform coated with genetically engineered macrophage membranes—called CXCR2-MM@PLGA/MT—to target the cells secreting CXC chemokines. CXCR2 overexpression on the macrophage membranes not only enhanced the targeting capacity of the nanoparticles but also prevented neutrophil infiltration via the scavenging of CXC chemokines. Meanwhile, the MT delivered to the site of injury successfully attenuated CXC chemokine release after macrophage polarization and hepatocyte necrosis by inhibiting NF-κB phosphorylation and inducing antioxidant effects. Through the synergistic effects of MT and the CXCL/CXCR axis-blocking function of the engineered nanoparticles, CXCR2-MM@PLGA/MT attenuated the aggregation of neutrophils at the site of injury, markedly reducing local inflammation and cellular damage following HIRI. This engineered cellular nanoparticle-based therapy could thus serve as a safe, effective, and cost-efficient strategy for treating HIRI.
Autor:innen und Institutionen
- Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
- College of Biomedical Engineering, Chongqing Medical University, Chongqing, China.
- Department of Orthopedic Oncology, Shanghai General Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
ORCID-Profile: Zuojin Liu
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Chongqing
- Chongqing Graduate Student Research and Innovation Programme
Zitieren
APA
Yang, L., Li, W., Huang, Z., Zhao, Y., Sun, Z., Wang, H., Cao, L., Lu, J., Sun, R., Ma, X., Shao, T., Wu, X., He, S., & Liu, Z. (2025). Engineered Macrophage Membrane-Coated Nanoparticles for Hepatic Ischemia–Reperfusion Injury Therapeutics. Biomaterials Research, 29. https://doi.org/10.34133/bmr.0212
Vancouver
Yang L, Li W, Huang Z, Zhao Y, Sun Z, Wang H, et al. Engineered Macrophage Membrane-Coated Nanoparticles for Hepatic Ischemia–Reperfusion Injury Therapeutics. Biomaterials Research. 2025;29. doi:10.34133/bmr.0212
BibTeX
@article{Yang2025,
author = {Yang, Long and Li, Weiwei and Huang, Zhen and Zhao, Yinping and Sun, Zhenwen and Wang, Haoyu and Cao, Longpo and Lu, Jiao and Sun, Ruirui and Ma, Xiang and Shao, Tianxin and Wu, Xixi and He, Siqi and Liu, Zuojin},
title = {Engineered Macrophage Membrane-Coated Nanoparticles for Hepatic Ischemia–Reperfusion Injury Therapeutics},
journal = {Biomaterials Research},
year = {2025},
volume = {29},
doi = {10.34133/bmr.0212}
}
EUVIMED